Search

Displaying results 7851 - 7860 of 10000 in total
  1. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose … of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).

  2. Drug

    Bumadizone

    go.drugbank.com/drugs/DB13286
    Approved

    Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis

  3. Drug

    Exametazime

    go.drugbank.com/drugs/DB11179
    Approved

    It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex. … It is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes.

  4. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.

  5. Drug

    Muparfostat

    go.drugbank.com/drugs/DB05808
    Investigational

    Muparfostat (PI-88) is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic

  6. Drug

    Sulfamethizole

    go.drugbank.com/drugs/DB00576
    ApprovedVet approved

    A sulfathiazole antibacterial agent.

  7. Drug

    BB 21217

    go.drugbank.com/drugs/DB17373
    Investigational

    BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP

  8. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. … As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.

  9. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

  10. Drug

    Licofelone

    go.drugbank.com/drugs/DB04725
    Experimental

    Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given. … It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis.